Clinical trial
A Prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07312578 is registered in ClinicalTrials.gov with Peking University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Peking University
- Phase
- Phase 2
- Overall status
- Enrolling by invitation
- Start date
- November 1, 2025
- Completion date
- November 1, 2027
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.